Subscribe to RSS
DOI: 10.1055/s-2004-824864
© Georg Thieme Verlag Stuttgart · New York
Insulinpumpentherapie bei Typ 1-Diabetes mellitus
Insulin pump treatment in type 1 diabetes mellitusPublication History
eingereicht: 10.2.2004
akzeptiert: 29.4.2004
Publication Date:
21 July 2004 (online)
Der Verlauf des Diabetes und seiner Folgekomplikationen bei einem Patienten hängt wesentlich von der Qualität der Stoffwechseleinstellung ab. In vielen Studien, herausragend in der DCCT [39] [40] [42], wurde dies nachgewiesen. Gegenüber der konventionellen Therapie zeigte sich die Überlegenheit der intensivierten Diabetestherapie mit ICT (intensivierte konventionelle Insulintherapie) oder CSII (kontinuierliche subkutane Insulin-Infusion). Entscheidender Vorteil der CSII ist die Möglichkeit der vollständigen Trennung und individuellen Steuerbarkeit von prandialer und basaler Insulinversorgung.
Die Einführung der Insulinpumpentherapie in die Behandlung des Typ 1-Diabetes erfolgte 1977 [7]. Damals galten ausgeprägte Blutglukoseschwankungen, Dawn-Phänomen, unregelmäßiger Tagesablauf und der Wunsch nach Flexibilität sowie die optimale Stoffwechselführung in der Schwangerschaft als Indikationen. Hypoglykämieprobleme stellten eine Kontraindikation dar. Mit Verbesserung der Pumpentechnik, mehr Sicherheit und effizienterer Patientenschulung sind die Indikationen erweitert worden. In den 90er-Jahren sank die Rate akuter Hypoglykämien unter CSII. Gegenüber der ICT lässt sich die Stoffwechseleinstellung unter CSII verbessern und die Häufigkeit schwerer Hypoglykämien reduzieren [24] [44]. Heute zählt die Hypoglykämieneigung zu den Hauptindikationen der Pumpentherapie. Bei Kindern und Jugendlichen wird die CSII seit 1979 eingesetzt, anfangs nur in Einzelfällen bei besonderen Problemen. Seit ca. 5 Jahren findet sie eine rasch zunehmende Verbreitung mit ähnlichen Indikationen wie bei Erwachsenen [3] [19] [36] [37] [43] [45].
Literatur
- 1 Arbeitsgemeinschaft Diabetes und Schwangerschaft der Deutschen Diabetes Gesellschaft . Die ärztliche Betreuung der schwangeren Diabetikerin. Diabetologie Informationen. 1997; 19 275-281
- 2 Attia N, Jones T W, Holcombe J. et al . Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Diabetes Care. 1998; 21 817-821
- 3 Boland E A, Grey M, Oesterle A, Fredrickson L, Tamborlane W. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes care. 1999; 22 1779-1784
- 4 Brunner G A, Hirschberger S, Sendlhofer G. et al . Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabetic Medicine. 2000; 17 371-375
- 5 Buchwald H, Rhode D T. et al . A totally implantable drug infusion device: Laboratory and clinical experience using a model with single flow rate and a new design for modulated insulin infusion. Diabetes Care. 1980; 3 351-358
- 6 Burkart W, Hanker J P, Schneider H PG. Complications and Fetal Outcome in Diabetic Pregnancy. Gynecol Obstet Invest. 1988; 26 104-112
- 7 Colquitt J, Royle P, Waugh N. Ara analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabetic Medicine. 2003; 20 863-866
- 8 Coustan D R, Reece E A, Sherwin R S, Rudolf M CJ, Bates S E, Sockin S M, Holford T, Tamborlane V. A randomized clinical trial of the insulin pump vs intensive conventional therapy in diabetic pregnancies. J Am Med Assoc. 1986; 255 631-636
- 9 Evers I M, De Valk H W, Mol B W, Ter Braak E W, Visser G H. Macrosomia despite good glycaemic control in Type I diabetic pregnancy: results of a nationwide study in The Netherlands. Diabetologia. 2002; 45 1484-1489
- 10 Feldberg D, Dicker D, Samuel N, Peleg D, Karp M, Goldman J A. Intrapartum Management of Insulin-Dependent Diabetes Mellitus (IDDM) Gestants. Acta Obstet Gynecol Scand. 1988; 67 333-338
- 11 Feldt-Rasmussen B, Mathiesen E R, Deckert T. et al . Effect of 2 years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet. 1986; 1 1300-1304
- 12 Gabbe S G, Holing E, Temple P, Brown Z A. Benefits, risks, costs, and patient satisfaction associated with insulin pump therapy for the pregnancy complicated by type 1 diabetes mellitus. Am J Obstet Gynecol. 2000; 182 1283-1291
- 13 Grey M, Boland E A, Davidson M, Li J, Tamborlane W. Coping skills training for youth on intensive therapy has long lasting effects on metabolic control and quality of life. Journal of Pediatrics. 2000; 137 107-114
- 14 Hanas R. Low risk of hypoglycemia despite metabolic control at DCCT level in a population of children and adolescents using intensified insulin treatment. Diabetes. 2000; 49 A133
- 15 Helve E, Laatikainene L, Merenmies L. et al . Continuous insulin infusion therapy and retinopathy in patients with type 1 diabetes. Acta Endocrinol (Copenhagen). 1987; 115 313-319
- 16 Irsigler K, Kritz H. et al . Long-term continuous intraperitoneal insulin infusion with an implanted remote-controlled insulin infusion device. Diabetes. 1981; 30 1072-1075
- 17 Jakobsen J, Christiansen J S, Kristoffersen I. et al . Autonomic and somatosensory nerve function after 2 years of continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes. 1988; 37 452-455
- 18 Jornsay D L. Continuous Subcutaneous Insulin Infusion (CSII) Therapie During Pregnancy. Diabetes Spectrum. 1998; 11 26-32
- 19 Kaufman F R, Halvorson M, Miller D, Mckenzie M, Fisher L K, Pitukcheewanont P. Insulin pump therapy in type 1 pediatric patients: now and into the year 2000. Diabetes Metabolism Research and Reviews. 1999; 15 338-352
- 20 Kitabchi A E, Fisher J N. et al . Evaluation of a portable insulin infusion pump for outpatient management of brittle diabetes. Diabetes Care. 1979; 2 421-424
- 21 Kitzmiller J L, Buchanan T A, Kjos S, Combs C A, Ratner R E. Pre-Conception Care of Diabetes, Congenital Malformations, and Spontaneous Abortions. Diabetes Care. 1996; 19 514-541
- 22 Klinkert C, Hertrampf K. et al . Kleinkinder mit Diabetes profitieren von der Insulinpumpentherapie. Diabetes und Stoffwechsel. 2002; 11 (Suppl 1) 78
- 23 Lawson P, Trayner I, Rosenstock J. et al . The effect of continuous subcutaneous insulin infusion on serum lipids. Diabetes Metabol. 1984; 10 239-244
- 24 Lenhard M J, Reeves G D. Continuous subcutaneous insulin infusion. Archives of Internal Medicine. 2001; 161 2293-2300
- 25 Ludvigsson J, Bolli G B. Intensive insulin treatment in diabetic children. Diabetes, Nutrition & Metabolism - Clinical & Experimental. 2001; 14 292-304
- 26 Melki V, Renard E, Lassman-Vague V. et al . Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care. 1998; 21 977-982
- 27 Mortensen H B, Hougaard P. Comparison of metabolic control in a cross-sectional study of 2873 children an adolescents with IDDM from 18 countries. Diabetes Care. 1997; 20 714-720
- 28 Quester W, Petzoldt R. Erfassung der prä- und postprandialen Hyperglykämie in der Schwangerschaft durch Einsatz eines Glucose-Sensors. Diabetes und Stoffwechsel. 2001; 10 83 (Suppl 1)
- 29 Rami B, Schober E. Postprandial glycemia after regular and lispro insulin in children and adolescents. European Journal of Pediatrics. 1997; 156 838-840
- 30 Renard E, Shah R. et al . Sustained safety and accuracy of central iv glucose sensors connected to implanted insulin pumps and short-term closed-loop trials in diabetic patients. Diabetes. 2003; 52 (Suppl 1) 155
- 31 Saudek C D, Duckworth W C. et al. Department of Veterans Affairs Implantable Insulin Pump Study Group . Implantable insulinpump vs multiple dose insulin for non insulin dependent diabetes mellitus a randomized clinical trial. JAMA. 1996; 276 1322-1327
- 32 Scherbaum W A. Kann Insulin Humalog in der Schwangerschaft gegeben werden?. Dtsch Med Wochenschr. 2003; 128 1190
- 33 Steindel B S, Roe T R, Costin G. et al . Continuous subcutaneous insulin infusion (CSII) in children and adolescents with poorly controlled type 1 diabetes. Diabetes Res Clin Pract. 1995; 27 199-204
- 34 Suhonen L, Hülesmaa V, Teramo K. Glycaemic control during early pregnancy and fetal malformations in women with Type 1 diabetes mellitus. Diabetologia. 2000; 43 79-82
- 35 Tamborlane W, Ahern J A. Implications and results of the diabetes control an complications trial. Pediatric Clinics in North America. 1997; 44 285-299
- 36 Tamborlane W, Sherwin R S, Genel M, Felig P. Reduction to normal plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. New England Journal of Medicine. 1979; 300 573-578
- 37 Tamborlane W, Sherwin R S, Genel M, Felig P. Outpatient treatment of juvenile-onset diabetes with a preprogrammed portable subcutaneous insulin infusion system. American Jourmal of Medicine. 1980; 68 190-196
- 38 Temple R, Aldridge V, Greenwood R, Heyburn P, Sampson M, Stanley K. Association between outcome of pregnancy and glycaemic control in early pregnancy in type 1 diabetes: population based study. BMJ. 2002; 325 1275-1276
- 39 The DCCT Research Group . The effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: the Diabetes Control and Complication Trial. Journal of Pediatrics. 1994; 125 177-188
- 40 The DCCT Research Group . Prolonged effect of intensive therapy on the risk of advanced complications in Epidemiology of Diabetes Intervention and Complications (EDIC) follow-up of the DCCT cohort. New England Journal of Medicine. 2000; 342 381-389
- 41 The DCCT Research Group . Pregnancy outcomes in the Diabetes Control and Complications Trial. Am J Obstet Gynecol. 1996; 174 1343-1353
- 42 The Diabetes Control and Complication Trial (DCCT) Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine. 1993; 329 977-986
- 43 Weintrob N, Benzaquen H. et al . Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. Pediatrics. 2003; 112 559-564
- 44 Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin Pump Therapy. Diabetes Care. 2003; 26 1079-1087
- 45 Willi S M, Planton J. et al . Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. Journal of Pediatrics. 2003; 143 796-801
- 46 Zinman B, Tildesley H, Chiasson J L. et al . Insulin lispro in CSII. Results of a double-blind crossover study. Diabetes. 1997; 46 440-443
C. Klinkert
Herz- und Diabeteszentrum Nordrhein-Westfalen, Diabeteszentrum
Georgstraße 11
32545 Bad Oeynhausen
Email: cklinkert@hdz-nrw.de